Dergiler / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 3

The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society

Sayfa
234–241
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

All of the items in the scale were included in the validity analysis owing to their reliability.Conclusion: The Turkish GIT 2.0 scale showed good internal consistency, high reliability, and an acceptable validity.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: To translate the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire from English to Turkish and to validate it.Materials and Methods: UCLA SCTC GIT 2.0 was translated into Turkish using the translation-retranslation method.
📊
Temel Bulgular & Veri:The available Turkish GIT 2.0 and the Short Form 36 (SF-36) were administered to 97 Turkish-speaking patients with systemic sclerosis (Ssc).
💡
Sonuç & Katkı:All of the items in the scale were included in the validity analysis owing to their reliability.Conclusion: The Turkish GIT 2.0 scale showed good internal consistency, high reliability, and an acceptable validity.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: To translate the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire from English to Turkish and to validate it.Materials and Methods: UCLA SCTC GIT 2.0 was translated into Turkish using the translation-retranslation method. The available Turkish GIT 2.0 and the Short Form 36 (SF-36) were administered to 97 Turkish-speaking patients with systemic sclerosis (Ssc). Internal consistency reliability and structural validity were assessed by analyzing the correlations between the UCLA SCTC GIT 2.0 and the SF-36 scales. Internal consistency was determined by calculating Cronbach’s alpha. For evaluation of reliability, the questionnaire scale was repeatedly applied to a subgroup of patients with a 2-week interval, and the intraclass correlation coefficient (ICC) was calculated. The Spearman’s correlation coefficients between the GIT and the SF-36 scores were calculated.Results: A group of 97 patients with Ssc with a mean age of 55.37±11.35 years and a female predominance (87.6%) were included in the study. The Cronbach’s alpha value for the UCLA SCTC GIT 2.0 scale was 0.894. ICC was 0.821 (p=0.000). The scale showed acceptable reliability, with the exception of the diarrhea subscale (alpha=0.356). There was a moderate correlation between the total GIT score and the Short Form 36 (SF-36) subscales. All of the items in the scale were included in the validity analysis owing to their reliability.Conclusion: The Turkish GIT 2.0 scale showed good internal consistency, high reliability, and an acceptable validity.

🔖

Bu Makaleye Atıf Yap

TAŞ, Y. M., HAKİM, G. D., KESKİNOĞLU, P., KENAR, G., YARKAN, H., ZENGİN, B., CAN, G., ÖNEN, F., AKKOÇ, N., BİRLİK, A. M., AKARSU, M. (2019). The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 3, 234–241. https://ajindex.com/articles/409268

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (5)

  1. Meijs J, Pors D, Vliet Vlieland TP, Huizinga TW, Schouffoer AA. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract In - strument (SCTC GIT) 2.0 into Dutch. Clin Exp Rheumatol 2014; 32: 41-8.
  2. Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387-400. [CrossRef] Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003. [CrossRef] Bae S, Allanore Y, Coustet B, Maranian P, Khanna D. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheu -matol 2011; 29: 15-21.
  3. Gyger G, Baron M. Gastrointestinal manifestations of scleroder -ma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 2012; 14: 22-9. [CrossRef] Sjogren RW, Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 569-75. [CrossRef] Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclero -sis. Curr Opin Rheumatol 2013; 25: 700-6. [CrossRef] Khanna D, Furst DE, Maranian P, et al. Minimally important differ -ences of the UCLA Scleroderma Clinical Trial Consortium Gastroin -testinal Tract Instrument. J Rheumatol 2011; 38: 1920-4. [CrossRef] Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the Uni - versity of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-63. [CrossRef] Gorga M, Mihai C, Soare AM, Dobrotă R, Gherghe AM, Stoica V. A Romanian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Clin Exp Rheumatol 2015; 33: 61-7.
  4. Gualtierotti R, Ingegnoli F, Two R, VERITAS study group, et al. Re-liability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in pa -tients with systemic sclerosis. Clin Exp Rheumatol 2015; 33: 55-60.
  5. Low AH, Xin X, Law WG, et al. Validation of the UCLA Scleroder -ma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Sin -gapore systemic sclerosis cohort. Clin Rheumatol 2017; 36: 1643-8. [CrossRef] Zekovic A, Damjanov N. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instru